The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
TRENDS Countering Abilify Cliff, Otsuka Sees New Drug Franchise Set Stage for Growth Path
February 23, 2018
-
ACADEMIA Major Drug Makers to Join in AMED Project to Develop “Organs on Chips” as New Tools for Drug Discovery
February 22, 2018
-
BUSINESS Aducanumab Trial Tweak “Common Decision” to Boost Statistical Confidence: Biogen CEO
February 21, 2018
-
BUSINESS Takeda’s Specialty Biz Unit Most Likely to Handle GI Meds, Entyvio Launch Apparently Eyed
February 20, 2018
-
REGULATORY Turning Point for Blood Products? Discussions on Basic Policy on Blood Law Moving Ahead
February 20, 2018
-
REGULATORY Chugai Hemophilia Drug, Novel Zoster Vaccine Set for Approval Review on March 2
February 19, 2018
-
REGULATORY 20 Gx Makers Flock to Aimix, Sawai Earns Approval for Tamiflu Copy for June Listing
February 16, 2018
-
BUSINESS Sumitomo Dainippon Sues 2 Gx Makers over Latuda, Delays New 5-Year-Plan Announcement
February 15, 2018
-
REGULATORY MHLW Looked at Balance and Made Major Revision Plans for Drug Pricing: Official
February 14, 2018
-
BUSINESS Pricing Revamp for Off-Patent Brands “Within Our Expectation”: LTL Pharma CEO
February 13, 2018
-
ORGANIZATION Private Univ. Group Encourages “Single-Product, Single-Price” Deals in Response to New Distribution GL, Tougher Medical Fee Cut Rules
February 9, 2018
-
TRENDS With 2 Players Closing in on Suglat, SGLT2 Inhibitors Entering Triangular Battle
February 8, 2018
-
REGULATORY Chuikyo Submits Recommendation for FY2018 Reimbursement Policy Reform, Drug Pricing Package Enshrined
February 8, 2018
-
BUSINESS EA Pharma Launches Rectabul, Boosts Efforts on Humira to Gird for IBD Showdown
February 7, 2018
-
BUSINESS Poxel Eyeing Japan as 1st Market for Its Lead Diabetes Candidate: CEO
February 6, 2018
-
BUSINESS PorMedTec to Support Development Using Disease Model Pigs, Clients Already Include One Major Drug Maker
February 6, 2018
-
REGULATORY Japan’s 1st Herceptin Biosimilar Clears MHLW Panel, Now in Line for March Approval for Gastric Cancer
February 5, 2018
-
INTERVIEW Interview: Pfizer Japan Looks to Offer High Quality Biosimilars with Go-It-Alone Strategy
February 2, 2018
-
ACADEMIA Overseas Meta-Analyses Find Increased Risk of CKD in Patients Who Use PPIs; Japanese Society of Nephrology Plans Study of Japanese Patients
February 2, 2018
-
BUSINESS Astellas Taps EVP Yasukawa as Next CEO
February 1, 2018
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…